121 results about "Vaccine antigen" patented technology

The invention discloses a broad-spectrum monoclonal antibody for resisting porcine epidemic diarrhea virus S protein and application of the broad-spectrum monoclonal antibody. Specifically, firstly, two monoclonal antibodies GC33D8-1 and GC33A4-3 which have broad-spectrum binding characteristics with the porcine epidemic diarrhea virus S protein are obtained, the GC33D8-1 antibody has good universality and can have strong affinity with different strains, and the GC33A4-3 antibody can be bound for 3 times. Secondly, the two monoclonal antibodies are respectively used as a capture antibody and a detection antibody, a double-antibody sandwich ELISA method is established, and the double-antibody sandwich ELISA method is applied to PEDV vaccine S protein quantification, has better parallelism compared with other antibodies, and can be widely applied to detection of different strains. The method can be used for detecting semi-finished products and finished products, can be used for process establishment and optimization of porcine epidemic diarrhea virus vaccine antigens, vaccine quality evaluation and stability monitoring, has the advantages of high sensitivity, high accuracy, high repeatability and high flux, and solves the problems that broad-spectrum detection cannot be carried out at present and an S protein ELISA method only can be used for qualitative judgment.

The invention discloses a monoclonal antibody and application thereof in quantitative detection of porcine epidemic diarrhea virus, and belongs to the technical field of biological detection. The preparation method comprises the following steps: firstly, obtaining two monoclonal antibodies GC44F3-1 and GC32C11-5 which specifically react with S protein of the porcine epidemic diarrhea virus; secondly, establishing a double-antibody sandwich ELISA (Enzyme-Linked Immunosorbent Assay) method by taking the two monoclonal antibodies as a coating antibody and a detection antibody respectively, and applying the double-antibody sandwich ELISA method to PEDV (Porcine Epidemic Diarrhea Virus) vaccine S protein quantification; the method can be used for detecting semi-finished products and finished products, can be used for process establishment, optimization, vaccine quality evaluation and stability monitoring of porcine epidemic diarrhea virus vaccine antigens, has the advantages of high sensitivity, high accuracy, high repeatability and high flux, is high in detection flux and high in speed, solves the problem that TCID50 cannot meet vaccine quality evaluation at present, and has a good application prospect. The defect that the existing S protein ELISA method can only be used for qualitative judgment is overcome. The monoclonal antibody can also be used for blocking ELISA, capturing ELISA, indirect ELISA, competitive ELISA and a reagent for detecting the porcine epidemic diarrhea virus through a colloidal gold test strip.

The invention belongs to the technical field of biological medicine, and particularly discloses a composite vaccine adjuvant as well as a preparation method and application thereof. The composite vaccine adjuvant provided by the invention is an oil-in-water emulsion, and simultaneously contains squalene, polysorbate 80, sorbitan trioleate, polyinosinic acid (Poly I: C) and CpG oligodeoxynucleotide (CpG-ODN). The sequence-optimized CpG-ODN and Poly I: C are used in a specific emulsion system in a combined mode, a remarkable synergistic immune enhancement effect can be generated, the induced humoral immunity and cellular immunity response level is remarkably higher than the sum of the effects when all the components are independently used, and the composite adjuvant is good in stability, high in immunostimulatory activity and suitable for clinical application. The immune effect can be remarkably improved by combined application with various vaccine antigens. The invention also provides a preparation method and application of the composite vaccine adjuvant.

The invention relates to the technical field of biological medicines, in particular to a soluble skin-adhering microneedle for delivering an inactivated enterovirus vaccine as well as a preparation method and application of the soluble skin-adhering microneedle. Sodium hyaluronate is adopted as a film forming material to wrap an enterovirus 71 type (EV71)-coxsackie virus A16 (CA16) type bivalent inactivated vaccine antigen, and a needle body layer of the soluble microneedle is formed; the substrate layer is prepared from a pullulan material, so that the microneedle patch with a stable overall structure is formed. The technology provided by the invention is completed in a clean environment, and the vaccine patch which is qualified through sterility detection is obtained. The soluble microneedle disclosed by the invention has good antigen stability under the condition of 2-8 DEG C. In animal experiments, the microneedle is attached to the skin surface of a mouse for skin-adhering immunization, a strong immune response reaction can be induced, good immunogenicity is shown, and a novel, safe and effective vaccine delivery way is provided for prevention and control of the infantile hand-foot-and-mouth disease.

This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and / or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

The invention relates to the technical field of biological medicines, in particular to a tuberculosis vaccine antigen and a vaccine. In particular to application of a mycobacterium tuberculosis Rv1787 gene in preparation of a vaccine for preventing and / or treating tuberculosis, in the application, the sequence of the Rv1787 gene or an encoding product thereof is defined, and the Rv1787 gene and the encoding product thereof serve as antigens, have mycobacterium tuberculosis specificity, and can be used for preparing a vaccine for preventing and / or treating tuberculosis. According to the mycobacterium tuberculosis vaccine, identification and response of an organism immune system to mycobacterium tuberculosis can be accurately stimulated, non-specific immune response to other normal tissues is avoided, a brand new and specific molecular target spot is provided for preventing and treating tuberculosis, and the limitation that a traditional vaccine depends on a single antigen or an attenuated strain is broken through. A specific expression product of the gene can stimulate directional recognition and attack of an organism immune system on mycobacterium tuberculosis, the pertinence and effectiveness of vaccines are remarkably improved, and a new path is provided for solving the problem of tuberculosis prevention and treatment.

The present invention relates to the technical field of biomedicine technology and vaccines, and particularly relates to an aluminum nanocrystal delivery system with a surface covered with an Fc affinity protein and a preparation method for a self-assembled particle adjuvant vaccine. An aluminum nanocrystal is used as a carrier, the surface of the aluminum nanocrystal is covered with an Fc affinity protein molecular layer and an antigen molecule, and the antigen of a recombinant Fc Tag specifically binds to an Fc affinity protein, so that antigen self-assembly is realized, a virus-like particle vaccine is formed, and the antigen density is improved. The present vaccine can generate a high-titer specific antibody by inducing a body fluid and cell immunity.

The application discloses a vaccine and a preparation method thereof, and the preparation method comprises the following steps: mixing an acidic protein antigen solution containing a phosphate buffer solution with an aluminum adjuvant to make the molar ratio of phosphorus and aluminum below 0.9, so as to obtain an acidic protein vaccine; or mixing the aluminum adjuvant with a solution containing phosphate ions to make the molar ratio of phosphorus and aluminum above 0.2, and then mixing the aluminum adjuvant with an alkaline protein antigen solution containing a phosphate buffer solution, so as to obtain an alkaline protein vaccine; wherein the acidic protein antigen is any kind of protein antigen with a net negative charge; and the alkaline protein antigen is any kind of protein antigen with a net positive charge. According to the preparation method, the molar ratio of phosphorus and aluminum is adjusted to a specific range according to the net charge of the protein antigen, so that the isoelectric point of the aluminum adjuvant can be effectively changed, the charge carried by the aluminum adjuvant is opposite to the charge carried by the protein antigen, and then the aluminum adjuvant and the protein antigen are attracted to each other through electrostatic interaction. The vaccine antigen prepared by the method has high antigen adsorption rate and good stability, the preparation method is simple, and the method is suitable for industrial application.

The present invention provides a fusion protein KP-Ag1 used as a Klebsiella pneumoniae vaccine antigen, which is composed of KP6 protein, KP21 protein and KP24 protein connected by a flexible amino acid Linker; wherein, the amino acid sequence of the KP6 is SEQ ID NO:4, the amino acid sequence of the KP21 is SEQ ID NO:5, and the amino acid sequence of the KP24 is SEQ ID NO:6. The present invention also provides its expression vector and recombinant engineering diagram, as well as its application as a Klebsiella pneumoniae antigen. The antigen protein prepared by the method described in the present invention can effectively stimulate the body to produce a higher humoral immune response, and can provide obvious protection against lethal-dose Klebsiella pneumoniae infection, and can be used as a candidate antigen for Klebsiella pneumoniae vaccine.

The application relates to the field of rapid detection of new coronaviruses, in particular to a single-layer MoS2 phase sensor detection box for a new coronavirus vaccine antigen protein and a detection method thereof. The process that a MoS2 test sample is combined with a standard new coronavirus SARS-CoV-2 antibody is as follows: firstly, single-layer MoS2 is grown through a CVD method; further, ZnO is deposited on SiO2 / Si through atomic layer deposition (ALD); the single-layer MoS2 is transferred to a substrate through PMMA (polymethyl methacrylate) assisted wet transfer; the surface of the MoS2 is subjected to surface treatment; and the problem that current detection methods can only qualitatively detect whether there is a new coronavirus and cannot measure a specific concentration is solved. On the premise of ensuring high sensitivity, the actual concentration of a sample can be quantitatively measured. The pretreatment process of the sample is simple, the detection process is short in time consumption, the measurement result is intuitive and accurate, and the application has important significance for quantitative detection of the concentration of a new coronavirus for a large number of samples.

Disclosed is a vaccine adjuvant comprising at least one inverse microlatex comprising at least one oil, at least one surfactant, at least one polymer, such as, for example, a fully or partially neutralized polyacrylate in the form of an alkali metal salt or an ammonium salt, which can be completely sterilized by filtration or by heating in an autoclave and can be emulsified in one step with an aqueous phase comprising only the vaccine antigen.

The invention relates to the technical field of biological medicines, and particularly discloses a diluent for a porcine pseudorabies live vaccine. The diluent for the porcine pseudorabies live vaccine is prepared by stirring and dissolving sodium dihydrogen phosphate, dipotassium phosphate, calcium chloride, sodium chloride, a traditional Chinese medicine extract, a stabilizer and water, and performing high-pressure steam sterilization, the traditional Chinese medicine extract is prepared by taking poria cocos and honeysuckle as traditional Chinese medicine raw materials and further reacting with chitosan and tannic acid, and the stabilizer is prepared by mixing gelatin, cyclodextrin and bovine serum albumin according to a mass ratio. When the diluent prepared by the method is used for diluting the porcine pseudorabies live vaccine, the stability and the activity of vaccine antigens can be effectively improved, the activity and the function of immune cells are enhanced, so that the immune effect of the vaccine is enhanced, and the prepared diluent for the porcine pseudorabies live vaccine solves the problem that a traditional live vaccine diluent does not have an immune enhancement effect.

Provided are virus-like particle vaccines for human metapneumovirus (hMPV) in which the ectodomain of hMPV F protein is linked to, and thereby displayed on, a symmetric protein-based virus-like particle. For example, the vaccine antigen may be a N-terminal fusion of the ectodomain of hMPV F protein to a protein having a multimerization domain for a one- or two-component virus-like particle, such as a two-component icosahedral virus-like particle. Further provided are vaccine compositions, methods of manufacturing, and methods of use, e.g., immunizing a subject to generate a protective immune response to hMPV.

The invention relates to a GnRH-I-M1 recombinant protein. A vaccine prepared from the GnRH-I-M1 recombinant protein is high in antigen purity and good in safety, and has a good castration effect.

The application provides a buffer for improving the stability of foot-and-mouth disease vaccine antigen, which contains milk serum, sodium chloride, sorbitol, glycine, K2HPO4.3H2O and KH2PO4. The buffer has the effects of improving the thermal stability of 146S antigen and obviously inhibiting the degradation of 146S antigen under the conditions of 4 DEG C and 37 DEG C. The antigen resuspended by the buffer and the prepared vaccine can be stored for a long time under the condition of 4 DEG C. In addition, the buffer is easy to prepare and dissolve, can be used as a medium for resuspending FMD antigen, is a good thermal stability protective agent for FMD antigen and vaccine, can be used in large-scale production, has strong practicability, can obviously reduce the degradation rate of effective antigen in foot-and-mouth disease vaccine under storage conditions and extreme conditions, and obviously improves the product quality.

The present invention discloses a monoclonal antibody capable of recognizing a novel duck reovirus NDRVσC protein, a preparation method and an application thereof, wherein the monoclonal antibody comprises a heavy chain variable region and a light chain variable region; the heavy chain variable region comprises a V sequence as shown in SEQ ID NOs: 3, 4, and 5. H CDR1, V H CDR2 and V H CDR3, the light chain variable region includes the amino acid sequences shown in SEQ ID NOs: 6, 7, and 8. L CDR1, V L CDR2 and V L CDR3. The present invention also discloses a method for preparing a monoclonal antibody and a double-antibody sandwich ELISA method based on the antibody and the σC rabbit polyclonal antibody. This method can be used to quantify NDRV subunit vaccine antigens and determine animal immunization doses. Compared with the methods reported in the literature, this ELISA method is simpler to operate and has great potential for practical application. The present invention provides a new method for evaluating NDRV immune efficacy and controlling vaccine quality, which can ensure the upgrading of NDRV vaccines.

A hybrid protein comprises a first domain comprising a sequence encoding a surface protein of an enveloped RNA virus and a second domain comprising a sequence encoding an ectodomain of a type 2 transmembrane domain protein, wherein the second domain is located at the C-terminal of the first domain. The hybrid protein or an mRNA encoding such protein can be used as a vaccine against the infection of the enveloped RNA virus.

The disclosure provides an animal cell stably expressing a virus-like particle (VLP). The disclosure also provides a method for manufacturing a virus-like particle, a virus-like particle, a vaccine composition, a method for preventing viral infection, and a method for producing antibodies.

This invention relates to a homogeneous photocatalytic chemiluminescence detection system for detecting HPV vaccine antigen content, its preparation method, and its application. The system utilizes self-made carboxyl-modified donor microspheres and receptor microspheres, coupled with HPV type-specific monoclonal antibodies via EDC / NHS activation, achieving one-step homogeneous detection. By optimizing the microsphere size, a 200 nm microsphere system was found to exhibit higher luminescence signal, a wider detection range, and better sensitivity when detecting HPV16 / 18 VLPs. This method is simple to operate, requires no plate washing, and possesses good specificity, accuracy, and precision. It is suitable for the in vitro relative potency and identification detection of bivalent HPV vaccines, and can replace traditional ELISA methods, reducing detection costs and safety risks. It is also suitable for large-scale applications in vaccine quality control.

The invention discloses a hepatocellular carcinoma prognosis and treatment adaptability evaluation model based on mRNA vaccine antigen and a construction method. The method comprises the following steps: firstly, analyzing gene expression difference between normal tissues and hepatocellular carcinoma tumors, understanding mutation and genome structure change of hepatocellular carcinoma patients, and then further selecting genes related to the infiltration level of antigen presenting cells from abnormally expressed genes and mutant genes, and the genes having a significant relationship with the overall lifetime and disease-free lifetime of the patient, so as to obtain candidate mRNA vaccine neoantigen targets. Based on the expression level of the target, immunotyping is performed on the patient, and the patient population suitable for the mRNA vaccine is evaluated. Meanwhile, the relationship between the expression level of the target spot and the prognosis of the patient is quantified, so that the probability value that the total survival time of the hepatocellular carcinoma patient reaches 3 years and 5 years is predicted. According to the invention, the hepatocellular carcinoma treatment resistance and tumor immune state can be objectively and accurately evaluated, and the prediction accuracy of hepatocellular carcinoma treatment prognosis is improved.

To provide HBV vaccines and methods for treating HBV.SOLUTION: Polypeptides are provided which are useful to elicit a protective immune response against one or more hepatitis B virus (HBV) antigens in a human. The immunogenic polypeptides described in this specification can elicit preventative and / or therapeutic immune responses in a human against one or more hepatitis B virus (HBV) antigens. Generally, the immunogenic polypeptides described in this specification contain highly conserved portions of HBV proteins in order to induce responses against epitopes that are identical in the vaccine antigen and in the infecting HBV present in the patient, while also excluding poorly conserved regions, thereby avoiding eliciting immunodominant T cell responses targeting epitopes that are not present in the infecting HBV strain of the patient.SELECTED DRAWING: Figure 1

Relates to the technical field of biology, in particular to a castrated PapMV virus-like particle subunit vaccine and a preparation method thereof. The invention provides the GnRH-I-PapMV recombinant protein which is high in purity and good in specificity. The vaccine prepared from the GnRH-I-PapMV recombinant protein is high in antigen purity, good in safety and good in castration effect.

This invention discloses a prognostic and therapeutic suitability assessment model for hepatocellular carcinoma (HCC) based on mRNA vaccine antigens, and its construction method. First, the differences in gene expression between normal tissues and HCC tumors are analyzed to understand the mutations and genomic structural changes in HCC patients. Then, genes related to the level of antigen-presenting cell infiltration, as well as genes significantly related to overall survival and disease-free survival, are further selected from anomalously expressed and mutated genes to obtain candidate mRNA vaccine neoantigen targets. Based on the expression levels of these targets, patients are immunophenotyped to assess the patient population suitable for mRNA vaccines. Simultaneously, the relationship between target expression levels and patient prognosis is quantified to predict the probability of HCC patients achieving 3-year and 5-year overall survival. This invention can objectively and accurately assess treatment resistance and tumor immune status in HCC, improving the predictive accuracy of HCC treatment prognosis.

Relates to the technical field of biology, in particular to a castrated HBsAg virus-like particle subunit vaccine and a preparation method thereof. The invention provides the GnRH-I-HBsAg recombinant protein which is high in purity and good in specificity. The vaccine prepared from the GnRH-I-HBsAg recombinant protein is high in antigen purity and good in safety, and has a good castration effect.

The application discloses a highly immature duck Tembusu virus, a culture method and application thereof, and belongs to the technical field of biotechnology.According to the method for culturing the highly immature duck Tembusu virus based on the LOVO cell line provided in the application, the duck Tembusu virus obtained by culture loses pathogenicity, the application provides a highly potential candidate strain for developing safe and effective duck Tembusu virus vaccines, opens up a new way for safely producing high-quality diagnostic antigens and vaccine antigens, and significantly reduces the biosafety risk of related research.

The application discloses an adjuvant containing Mycobacterium vaccae surface polysaccharide and application thereof, and the adjuvant comprises: Mycobacterium vaccae surface polysaccharide, wherein the Mycobacterium vaccae surface polysaccharide comprises: LAM polysaccharide, and LM polysaccharide and / or PIMs polysaccharide. The adjuvant of the application can improve the immunization effect of a vaccine antigen component and has good safety. Therefore, the adjuvant of the application can further improve the prevention and / or treatment effect of a vaccine, and has a wide application prospect.

The invention relates to a castrated TMV virus-like particle subunit vaccine and a preparation method thereof. The GnRH-I-TMV recombinant protein is high in purity and good in specificity. A vaccine prepared from the GnRH-I-TMV recombinant protein is high in antigen purity, good in safety and good in castration effect.

The invention relates to a multi-antigen component PEI lipid delivery system and an anti-avian influenza virus multivalent vaccine comprising the same, belongs to the technical field of biological medicines, and provides a delivery system consisting of PEI, squalene, cholesterol and mPEG. The preparation method comprises the following steps of: constructing mRNA (messenger ribonucleic acid) molecules and a composite vaccine antigen system consisting of prokaryotic expression purified H7N9 avian influenza NP antigen, loading the composite vaccine antigen system into a delivery system to obtain the nanoparticles with a virus-like structure, and displaying the HA protein antigen and the NP antigen in the structure of the nanoparticles in a particle form by the nanoparticles, so that the nanoparticles can be used for preparing the H7N9 avian influenza NP / H7N9 avian influenza NP / H7N9 avian influenza NP / H7N9 avian influenza virus. And the mRNA molecule for coding the NA antigen, which is combined with the mRNA molecule, can be delivered into a cell in a manner of fusing lipid and a cell membrane, so that the mRNA molecule can be effectively expressed to induce a body to generate specific antibody reactions aiming at HA, NA and NP, and the body can also generate specific CTL reactions aiming at HA, NA and NP of different influenza virus strain subtypes.